Global Cord Blood (NYSE:CORBF) & Progyny (NASDAQ:PGNY) Critical Review

Progyny (NASDAQ:PGNYGet Free Report) and Global Cord Blood (NYSE:CORBFGet Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.


This table compares Progyny and Global Cord Blood’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Progyny 5.53% 11.95% 8.49%
Global Cord Blood N/A N/A N/A

Analyst Ratings

This is a summary of recent ratings for Progyny and Global Cord Blood, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Progyny 0 1 9 0 2.90
Global Cord Blood 0 0 0 0 N/A

Progyny presently has a consensus price target of $46.11, indicating a potential upside of 67.49%. Given Progyny’s higher possible upside, analysts clearly believe Progyny is more favorable than Global Cord Blood.

Insider and Institutional Ownership

94.9% of Progyny shares are owned by institutional investors. 12.3% of Progyny shares are owned by company insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Progyny has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500.

Earnings and Valuation

This table compares Progyny and Global Cord Blood’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Progyny $1.09 billion 2.43 $62.04 million $0.61 45.13
Global Cord Blood $196.12 million 0.77 $79.04 million N/A N/A

Global Cord Blood has lower revenue, but higher earnings than Progyny.


Progyny beats Global Cord Blood on 10 of the 11 factors compared between the two stocks.

About Progyny

(Get Free Report)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

About Global Cord Blood

(Get Free Report)

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with's FREE daily email newsletter.